Conditions: Hepatitis C Virus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 881
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Peginterferon Lambda-1a intervention 2: Peginterferon Alfa-2a intervention 3: Ribavirin intervention 4: Telaprevir
Intervention descriptions: intervention 1: Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response intervention 2: Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response intervention 3: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response intervention 4: Tablets, Oral, 750 mg, three times a day, 12 weeks only

Protocol document: